

## PHARMACY POLICY STATEMENT

### Ohio Medicaid

DRUG NAME	Avastin (bevacizumab)
BILLING CODE	J7999, J3490 and J3590
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Office/Outpatient
STATUS	Prior Authorization Required

Bevacizumab was initially approved by the FDA in 2004 as Avastin®. Avastin® (bevacizumab) is a drug used in the treatment of wet age-related macular degeneration, diabetic eye disease and other problems of the retina. Avastin® (bevacizumab) is injected into the eye and helps to slow down disease related vision loss. The use of Avastin® to treat eye disease is considered “off-label”, which is allowed by the FDA when doctors are well informed regarding the drug and there are studies that support its efficacy as a treatment

References:

1. Alysmsys. Package insert. Amneal Pharmaceuticals LLC; 2022.
2. Avastin. Package insert. Genentech; 2004.
3. Mvasi. Package insert. Amgen Inc; 2017.
4. Zirabev. Package insert. Pfizer Inc; 2019.
5. What is Avastin <https://www.aao.org/eye-health/drugs/avastin>
6. "Off-Label" and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices - Information Sheet. (2018, July 12). Retrieved October 29, 2018, from <https://www.fda.gov/regulatoryinformation/guidances/ucm126486.htm>
7. Avastin Prescribing Information [https://www.gene.com/download/pdf/avastin\\_prescribing.pdf](https://www.gene.com/download/pdf/avastin_prescribing.pdf)
8. CMS Billing and Coding: Bevacizumab and biosimilars <https://www.cms.gov/medicare->